Clinical trial

Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate

Name
AAAS2051
Description
This study will investigate the effect of coral calcium complex supplementation on BMD of osteoporotic individuals either when used alone or in combination with ibandronate. Ibandronate alone will also be tested in comparison to coral calcium supplementation alone or in combination.
Trial arms
Trial start
2020-02-05
Estimated PCD
2023-03-13
Trial end
2023-03-13
Status
Completed
Phase
Early phase I
Treatment
Coral Complex 3
Coral-derived calcium supplement fortified with vitamin D3
Arms:
Coral calcium complex, Coral calcium complex and ibandronate
Ibandronate
Bisphosphonate
Arms:
Coral calcium complex and ibandronate, Ibandronate and vitamin D
Vitamin D3
Oral vitamin D3
Arms:
Ibandronate and vitamin D
Size
60
Primary endpoint
Mean change in bone mineral density (BMD) (lumbar spine)
48 weeks
Mean change in BMD (femoral neck)
48 weeks
Mean change in BMD (total hip)
48 weeks
Mean change in BMD (forearm)
48 weeks
Eligibility criteria
Inclusion Criteria: 1. Postmenopausal women, 50-75 years of age (inclusive). Menopause is defined as no menstrual period for 1 year. 2. BMD T-score of lumbar spine (L1-L4), femoral neck, total hip, or non-dominant forearm \< -2.5 as determined by DXA. Exclusion Criteria: 1. T-score of lumbar spine, femoral neck, total hip, or non-dominant forearm \< -3.5. 2. Use of any supplemental calcium preparations in the past 1 year. 3. Use of ibandronate in the past 3 years. 4. Current use of 1. prednisone or other corticosteroid, 2. antiseizure medications, 3. thiazide diuretics, or 4. estrogen preparation except vaginal cream. 5. Electrolyte abnormalities, as defined by abnormal blood levels of sodium (Na), chlorine (Cl), potassium (K), phosphate (Phos), calcium (Ca), or magnesium (Mg) values on initial screen. 6. Chronic disease, including 1. liver disease (as defined by elevated blood levels of aspartate aminotransferase, alanine aminotransferase, and/or alkaline phosphatase or reduced albumin or total protein on initial screen), 2. stage III renal disease or worse (as defined by epidermal growth factor receptor (eGFR) \< 60 cc/min), 3. abnormal thyroid function tests, 4. current parathyroid disease (as defined by hypercalcemia and elevated levels of parathyroid hormone (PTH) - if history of hyperparathyroidism, surgical cure has to be documented more than 5 years ago), 5. diabetes mellitus, 6. any other known metabolic bone disease besides osteoporosis, and/or 7. any inflammatory, anatomic, or malabsorptive GI tract disease. 7. Osteoporotic fracture in the past 6 months, defined as a low-energy fracture such as a fracture after falling from a standing height.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2024-05-09

1 organization

1 product

2 indications

Indication
Osteoporosis
Indication
Postmenopausal